Effect of Paclitaxel Combined with Nedaplatin on Serum Tumor Markers, MMP-9 and VEGF Levels in Patients with Endometrial Cancer

Abstract

Objective. \xa0To evaluate the effects\xa0of paclitaxel combined with nedaplatin on serum tumor markers, MMP-9 and VEGF levels in patients with endometrial cancer. Methods. \xa0The clinical data of 104 patients with endometrial cancer diagnosed and treated by the Obstetrics and Gynecology Hospital of Nanjing Medical University from January 2018 to January 2019 were retrospectively analyzed. The root randomized number method was divided into two groups. The control group (50 cases) received conventional cisplatin + doxorubicin + cyclophosphamide (CAP) regimen chemotherapy; the study group (54 patients) received paclitaxel + nedaplatin (TP) chemotherapy Interventions were used to compare the changes of tumor markers before and after chemotherapy, the changes of MMP-9 and VEGF levels and the adverse reactions after chemotherapy. Results After chemotherapy, serum tumor markers, MMP-9 and VEGF levels were significantly decreased in the two groups, but the overall level of chemo- therapy in the study group was significantly lower than that in the control group, with statistically differences (P<0.05). The incidence of drug side effects in the study group was significantly lower than that of the control group, with statistically significant difference (P<0.05) . Conclusions Paclitaxel + nedaplatin can significantly reduce the levels of MMP-9, VEGF and tumor markers in patients with endometrial cancer, and can effectively prevent the occurrence of toxic side effects, which is worthy of promotion.